Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meclofenamic Acid and Pentosan Polysulfate Sodium for Psychotic Disorders
NCT02930005Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Meclofenamic acid, pentosan polysulfate sodium in psychotic disorder, schizophrenia, schizoaffective disorder, bipolar disorder (BD), sponsored by UTHealth Houston. Started Aug 2015; status: completed.
02
Drugs
Meclofenamic acidpentosan polysulfate sodium
03
Conditions
psychotic disorderschizophreniaschizoaffective disorderbipolar disorder (BD)
Beyond the preview
Go deeper on NCT02930005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930005.